Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review
Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi. Thus, disease remission is a potential goal of urate...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/16/6/779 |
| _version_ | 1827736003020849152 |
|---|---|
| author | Adwoa Dansoa Tabi-Amponsah Sarah Stewart Graham Hosie Lisa K. Stamp William J. Taylor Nicola Dalbeth |
| author_facet | Adwoa Dansoa Tabi-Amponsah Sarah Stewart Graham Hosie Lisa K. Stamp William J. Taylor Nicola Dalbeth |
| author_sort | Adwoa Dansoa Tabi-Amponsah |
| collection | DOAJ |
| description | Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi. Thus, disease remission is a potential goal of urate-lowering therapy. In 2016, preliminary gout remission criteria were developed by a large group of rheumatologists and researchers with expertise in gout. The preliminary gout remission criteria were defined as: serum urate < 0.36 mmol/L (6 mg/dL); an absence of gout flares; an absence of tophi; pain due to gout < 2 on a 0–10 scale; and a patient global assessment < 2 on a 0–10 scale over a 12-month period. In this critical review, we describe the development of the preliminary gout remission criteria, the properties of the preliminary gout remission criteria, and clinical studies of gout remission in people taking urate-lowering therapy. We also describe a future research agenda for gout remission. |
| first_indexed | 2024-03-11T02:02:47Z |
| format | Article |
| id | doaj.art-0dc4acff76764272a8d07913ed001939 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-11T02:02:47Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-0dc4acff76764272a8d07913ed0019392023-11-18T12:01:22ZengMDPI AGPharmaceuticals1424-82472023-05-0116677910.3390/ph16060779Gout Remission as a Goal of Urate-Lowering Therapy: A Critical ReviewAdwoa Dansoa Tabi-Amponsah0Sarah Stewart1Graham Hosie2Lisa K. Stamp3William J. Taylor4Nicola Dalbeth5Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New ZealandSchool of Clinical Sciences, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland 0627, New ZealandDepartment of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New ZealandDepartment of Medicine, University of Otago, Christchurch 8011, New ZealandDepartment of Medicine, University of Otago, Wellington 6242, New ZealandDepartment of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New ZealandUrate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi. Thus, disease remission is a potential goal of urate-lowering therapy. In 2016, preliminary gout remission criteria were developed by a large group of rheumatologists and researchers with expertise in gout. The preliminary gout remission criteria were defined as: serum urate < 0.36 mmol/L (6 mg/dL); an absence of gout flares; an absence of tophi; pain due to gout < 2 on a 0–10 scale; and a patient global assessment < 2 on a 0–10 scale over a 12-month period. In this critical review, we describe the development of the preliminary gout remission criteria, the properties of the preliminary gout remission criteria, and clinical studies of gout remission in people taking urate-lowering therapy. We also describe a future research agenda for gout remission.https://www.mdpi.com/1424-8247/16/6/779goutgout remissionpreliminary gout remission criteriaurate-lowering therapy |
| spellingShingle | Adwoa Dansoa Tabi-Amponsah Sarah Stewart Graham Hosie Lisa K. Stamp William J. Taylor Nicola Dalbeth Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review Pharmaceuticals gout gout remission preliminary gout remission criteria urate-lowering therapy |
| title | Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review |
| title_full | Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review |
| title_fullStr | Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review |
| title_full_unstemmed | Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review |
| title_short | Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review |
| title_sort | gout remission as a goal of urate lowering therapy a critical review |
| topic | gout gout remission preliminary gout remission criteria urate-lowering therapy |
| url | https://www.mdpi.com/1424-8247/16/6/779 |
| work_keys_str_mv | AT adwoadansoatabiamponsah goutremissionasagoalofurateloweringtherapyacriticalreview AT sarahstewart goutremissionasagoalofurateloweringtherapyacriticalreview AT grahamhosie goutremissionasagoalofurateloweringtherapyacriticalreview AT lisakstamp goutremissionasagoalofurateloweringtherapyacriticalreview AT williamjtaylor goutremissionasagoalofurateloweringtherapyacriticalreview AT nicoladalbeth goutremissionasagoalofurateloweringtherapyacriticalreview |